Sai Parenteral’s IPO open date is March 24, 2026, and the IPO will close on March 27, 2026. Sai Parenteral’s IPO is a Book build Issue. The company plans to raise around ₹409 crores via IPO, which comprises a fresh issue of ₹285.00 crores and an offer for sale up to 35,00,000 equity shares with a face value of ₹5 each.
The company reported revenue of ₹163.74 crores in 2025 against ₹155.18 crores in 2024. The company reported a profit of ₹14.43 crores in 2025 against a profit of ₹8.42 crores in 2024. As per the financials, the IPO investors should apply for the IPO for the long term.
Sai Parenteral’s IPO price band is ₹372 to ₹392 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Sai Parenteral’s IPO to list on BSE, NSE on April 2, 2026. The allotment of Sai Parenteral’s IPO date is March 30, 2026.(ipo updates)
📅 Sai Parenteral’s IPO
| Event | Date |
|---|---|
| IPO Open Date | 24 March 2026 |
| IPO Close Date | 27 March 2026 |
| Anchor Investor Bidding | 23 March 2026 |
| Allotment Date | 28–31 March 2026 (Expected) |
| Refund Initiation | Early April 2026 |
| Listing Date | Early April 2026 |
👉 As per the latest updates, IPO will open from 24 March 2026. (The Times of India)
💰 Sai Parenteral’s IPO Price Band
| Details | Value |
|---|---|
| Price Band | ₹372 – ₹392 per share |
| Face Value | ₹5 per share |
| Issue Type | Book Built Issue |
👉 Price band officially announced between ₹372–₹392. (The Times of India)
📊 IPO Size & Structure
| Component | Details |
|---|---|
| Fresh Issue | ₹285 Crore |
| Offer for Sale (OFS) | Up to 35,00,000 shares |
| Total Issue Size | Approx ₹400–₹450 Cr (Estimated) |
| Listing | NSE & BSE |
👉 IPO includes both fresh issue and OFS. (Angel One)
📦 IPO Reservation
| Category | Reservation |
|---|---|
| QIB | ≤ 50% |
| NII (HNI) | ≥ 15% |
| Retail Investors | ≥ 35% |
👉 Standard SEBI allocation structure. (Business Standard)
🏢 Company Overview
Sai Parenteral Limited is a pharmaceutical formulation company established in 2013.
Key Business Segments:
- Branded generic medicines
- Contract Development & Manufacturing (CDMO)
- Injectables & oral formulations (Sai Parenteral’s)
Product Categories:
- Cardiovascular
- Anti-diabetic
- Antibiotics
- Dermatology
- Gastroenterology
- Vitamins & supplements
👉 The company exports to Australia, the Middle East, Africa & Southeast Asia. (Business Standard)
🏭 Manufacturing Facilities
| Details | Info |
|---|---|
| Total Plants | 5 |
| Location | Mainly Hyderabad |
| Capabilities | Injectables, tablets, capsules |
👉 Strong manufacturing base in India. (Business Standard)
💸 Objects of the Issue
| Purpose | Amount (₹ Crore) |
|---|---|
| Capacity Expansion | 110.7 |
| R&D Centre | 18 |
| Debt Repayment | 20 |
| Working Capital | 33 |
| Overseas Investment | 36 |
| General Corporate | Remaining |
👉 Funds will support expansion and global growth. (Business Standard)
📈 Financial Performance
| Financial Year | Revenue | EBITDA | PAT |
|---|---|---|---|
| FY24 | ₹153.7 Cr | ₹31.7 Cr | ₹8.4 Cr |
| FY25 | ₹163.1 Cr | ₹39.4 Cr | ₹14.45 Cr |
Growth Highlights:
- Revenue growth: ~6%
- EBITDA growth: ~24%
- PAT growth: ~72%
👉 Strong profit growth indicates improving margins. (Business Standard)
⚠️ Risk Factors
- High dependence on the injectables segment
- Regulatory risks in global markets
- High working capital requirement
- Exposure to government pricing
👉 These risks are mentioned in the DRHP analysis.
👍 Strengths
- Diversified pharma portfolio
- Export presence
- Strong EBITDA growth
- Expansion + R&D focus
👎 Weaknesses
- Moderate revenue growth
- Regulatory dependency
- Competitive pharma industry
📊 Sai Parenteral’s IPO Review (Expert View)
| Factor | Rating |
|---|---|
| Financial Growth | ⭐⭐⭐⭐ |
| Industry Outlook | ⭐⭐⭐⭐ |
| Risk Level | ⭐⭐⭐ |
| Overall | ⭐⭐⭐⭐ (Good for long-term) |
👉 Suitable for moderate risk investors.
🧾 Lot Size (Expected)
| Category | Shares |
|---|---|
| Minimum Lot | ~38–40 shares |
| Investment | ₹15,000 approx |
(Final lot size will be confirmed in RHP)
📌 Peer Comparison Table (DRHP Based)
| Company Name | Face Value (₹) | Revenue (₹ Cr) | EPS (₹) | P/E (x) | RoNW (%) | NAV (₹) |
|---|---|---|---|---|---|---|
| Sai Parenteral’s Ltd | 5 | 163.1 | 5.43 | NA | 15.09% | 35.98 |
| Sai Life Sciences Ltd | 1 | 1694.5 | 8.83 | 107.99 | 7.99% | 102.12 |
| Innova Captab Ltd | 10 | 1243.6 | 22.41 | 37.47 | 13.37% | 167.66 |
| Senores Pharmaceuticals Ltd | 10 | 398.2 | 16.12 | 55.08 | 7.18% | 176.37 |
| Gland Pharma Ltd | 1 | 5616.5 | 42.40 | 46.53 | 7.63% | 555.41 |
🔍 Key Insights from Peer Comparison
📈 1. Size Comparison (Revenue)
- Sai Parenteral is much smaller than peers
- Revenue ₹163 Cr vs:
- ₹1200–5600 Cr for competitors
👉 Indicates early growth-stage company
💰 2. Profitability (EPS)
- EPS ₹5.43 is lower than most peers
- Peers like:
- Innova Captab → ₹22+
- Gland Pharma → ₹42+
👉 Suggests lower earnings base currently
📊 3. Return on Net Worth (RoNW)
- Sai Parenteral → 15.09% (higher than many peers)
- Peers mostly in 7–13% range
👉 Strong point: better capital efficiency
📉 4. Valuation (P/E Ratio)
- P/E not disclosed yet (IPO pricing stage)
- Peer P/E range:
- 37x to 108x
👉 If priced reasonably → valuation advantage possible
🏦 5. Net Asset Value (NAV)
- Sai Parenteral NAV: ₹35.98
- Peers: ₹100 – ₹555
👉 Lower NAV reflects smaller balance sheet size
⚖️ Overall Peer Positioning
| Factor | Position |
|---|---|
| Company Size | ❌ Small |
| Growth Potential | ✅ High |
| Profitability | ⚠️ Moderate |
| Capital Efficiency | ✅ Strong |
| Valuation Scope | ✅ Attractive (if priced right) |
🧠 Final Peer Comparison Verdict
👉 Sai Parenteral is a small but high-growth pharma player
- ✔ Strong RoNW (better than peers)
- ✔ Expansion-driven business
- ❌ Smaller scale vs competitors
- ❌ Lower earnings base
🏢 Sai Parenteral’s IPO – Company & Registrar Office Details
📍 Company Registered Office
| Particulars | Details |
|---|---|
| Company Name | Sai Parenteral’s Limited |
| Registered Office Address | Plot No. 39, 4th / 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad – 500032, Telangana, India |
| Phone | +91 9398877486 |
| enquiry@saiparenterals.com | |
| CIN | U24231TG2001PLC036043 |
👉 The company is registered in Hyderabad and operates from the Gachibowli business hub.
🧾 IPO Registrar Details
| Particulars | Details |
|---|---|
| Registrar Name | Bigshare Services Pvt Ltd |
| Phone | +91-22-62638200 |
| ipo@bigshareonline.com | |
| Website | https://ipo.bigshareonline.com |
DISCLAMER
The information shared here is intended solely for educational and general awareness purposes. Any securities, investments, or IPO-related details mentioned should not be interpreted as financial advice or investment recommendations. Readers are encouraged to conduct their own independent research or seek guidance from a qualified financial professional before making investment decisions.
IPO-related updates are provided for informational use only. Market trends, past performance, or investor interest do not ensure future outcomes. We are not registered with SEBI. Investments in IPOs and the securities market involve inherent risks, and individuals should carefully evaluate their financial situation or consult a certified financial advisor before investing.
